Searched for:
(1 - 11 of 11)
document
Heusinkveld, H. (author), Braakhuis, H. (author), Gommans, R. (author), Botham, P. (author), Corvaro, M. (author), van der Laan, J.W. (author), Lewis, D. (author), Madia, F. (author), Manou, I. (author), Schorsch, F. (author), Wolterink, G. (author), Woutersen, R. (author), Corvi, R. (author), Mehta, J. (author), Luijten, M. (author)
Chemical substances are subjected to assessment of genotoxic and carcinogenic effects before being marketed to protect man and the environment from health risks. For agrochemicals, the long-term rodent carcinogenicity study is currently required from a regulatory perspective. Although it is the current mainstay for the detection of nongenotoxic...
article 2020
document
Sewell, F. (author), Strupp, C. (author), van der Laan, J.W. (author), Wolf, D.C. (author), Wolterink, G. (author), Woutersen, R. (author), Zvonar, Z. (author), Heusinkveld, H. (author), Braakhuis, H. (author)
Currently the only methods for non-genotoxic carcinogenic hazard assessment accepted by most regulatory authorities are lifetime carcinogenicity studies. However, these involve the use of large numbers of animals and the relevance of their predictive power and results has been scientifically challenged. With increased availability of innovative...
article 2020
document
Braakhuis, H.M. (author), Slob, W. (author), Olthof, E.D. (author), Wolterink, G. (author), Zwart, E.P. (author), Gremmer, E.R. (author), Rorije, E. (author), van Benthem, J. (author), Woutersen, R. (author), van der Laan, J.W. (author), Luijten, M. (author)
Non-genotoxic carcinogens (NGTXCs) do not cause direct DNA damage but induce cancer via other mechanisms. In risk assessment of chemicals and pharmaceuticals, carcinogenic risks are determined using carcinogenicity studies in rodents. With the aim to reduce animal testing, REACH legislation states that carcinogenicity studies are only allowed...
article 2018
document
Braakhuis, J.G. (author), Tempelman, F. (author), Kluiters, C.E. (author), TNO Defensie en Veiligheid (author)
How can you stay in control when your short term needs swamp your long term interests? Increasingly, the Dutch Defence has to balance contradicting needs. On the one hand, ongoing operations require to field new capabilities as soon as possible, but on the other hand, new capabilities need to be tested and evaluated before fielding them....
conference paper 2008
document
Braakhuis, B.J.M. (author), Welters, M.J.P. (author), Cloos, J. (author), Pankras, J.E. (author), Smeets, S.J. (author), Fichtinger-Schepman, A.-M.J. (author), Centraal Instituut voor Voedingsonderzoek TNO (author)
The aim of the present study was to investigate how normal head and neck epithelial cells (NHNEC) respond to cisplatin compared to their neoplastic counterparts with respect to intracellular platinum (Pt) levels and growth inhibition. A colorimetric assay was used to assess growth inhibition after exposure to cisplatin for 72 h. Growth...
article 1999
document
Welters, M.J.P. (author), Braakhuis, B.J.M. (author), Jacobs-Bergmans, A.J. (author), Kegel, A. (author), Baan, R.A. (author), van der Vijgh, W.J.F. (author), Fichtinger-Schepman, A.M.J. (author)
article 1999
document
Welters, M.J.P. (author), Fichtinger-Schepman, A.M.J. (author), Baan, R.A. (author), Jacobs-Bergmans, A.J. (author), Kegel, A. (author), van der Vijgh, W.J.F. (author), Braakhuis, B.J.M. (author)
Total platinum contents and cisplatin-DNA adduct levels were determined in vivo in xenografted tumour tissues in mice and in vitro in cultured tumour cells of head and neck squamous cell carcinoma (HNSCC), and correlated with sensitivity to cisplatin. In vivo, a panel of five HNSCC tumour lines growing as xenografts in nude mice was used. In...
article 1999
document
Welters, M.J.P. (author), Braakhuis, B.J.M. (author), Jacobs-Bergmans, A.J. (author), Kegel, A. (author), Baan, R.A. (author), van der Vijgh, W.J.F. (author), Fichtinger-Schepman, A.M.J. (author), Centraal Instituut voor Voedingsonderzoek TNO TNO Voeding (author)
Background: Response to cisplatin-therapy is assumed to be related to the formation of platinum (Pt)-DNA adducts. Measurement of these adducts prior to therapy could be of value to improve cisplatin based cancer therapy. Materials and methods: We determined Pt-GG and Pt-AG adduct levels by use of 32P-postlabeling after ex vivo cisplatin...
article 1999
document
Braakhuis, B.J.M. (author), Welters, M.J.P. (author), Cloos, J. (author), Pankras, J.E. (author), Smeets, S.J. (author), Fichtinger-Schepman, A.M.J. (author)
article 1999
document
Welters, M.J.P. (author), Fichtinger-Schepman, A.M.J. (author), Baan, R.A. (author), Flens, M.J. (author), Scheper, R.J. (author), Braakhuis, B.J.M. (author), Centraal Instituut voor Voedingsonderzoek TNO (author)
Resistance to chemotherapy is a major problem in the treatment of patients with head and neck squamous cell carcinoma (HNSCC). Important factors involved are drug detoxification by glutathione (GSH) and reduced drug accumulation due to active transport out of the cell by so-called 'multidrug resistance-related proteins'. We have studied a panel...
article 1998
document
Braakhuis, B.J.M. (author), Klaassen, I. (author), van der Leede, B.M. (author), Cloos, J. (author), Brakenhoff, R.H. (author), Copper, M.P. (author), Teerlink, T. (author), Hendriks, H.F.J. (author), van der Saag, P.T. (author), Snow, G.B. (author), Centraal Instituut voor Voedingsonderzoek TNO (author)
Retinoids can reverse potentially premalignant lesions and prevent second primary tumours in patients with head and neck squamous cell carcinoma (HNSCC). Furthermore, it has been reported that acquired resistance to all-trans retinoic acid (RA) in leukaemia is associated with decreased plasma peak levels, probably the result of enhanced retinoid...
article 1997
Searched for:
(1 - 11 of 11)